Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509739 | 0.75 | CA2 (0.35) | CA2 | |
| SCHEMBL9664627 | 0.75 | CA2 (0.32) | CA2 | |
| SCHEMBL243965 | 0.72 | — | — | |
| SCHEMBL2480054 | 0.72 | — | — | |
| SCHEMBL2540229 | 0.72 | — | — | |
| SCHEMBL20530461 | 0.72 | CA2 (0.33) | CA2 | |
| SCHEMBL10770158 | 0.70 | CA2 (0.33) | CA2 | |
| SCHEMBL12047582 | 0.70 | CA2 (0.44) | CA2 | |
| SCHEMBL11903395 | 0.69 | HCRTR2 (0.33) | CA2 | |
| SCHEMBL16280834 | 0.69 | HCRTR2 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200388884-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND ENERGY DEVICE INCLUDING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-12-10 | — | — | US | disclosed |
| US-20200388887-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND ELECTRICAL STORAGE DEVICE INCLUDING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-12-10 | — | — | US | disclosed |
| US-10777850-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190051941-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-02-14 | — | — | US | disclosed |
| US-10177414-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte secondary battery using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-01-08 | — | — | US | disclosed |
| EP-3098893-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME | MITSUBISHI CHEM CORP (JP) | 2017-11-29 | — | — | EP | disclosed |
| US-20170224691-A1 | PDE INHIBITORS IN IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2017-08-10 | — | — | US | disclosed |
| US-20170224691-A1 | PDE INHIBITORS IN IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY | 2017-08-10 | — | — | US | disclosed |
| US-20170015709-A1 | GLYCOPEPTIDE DERIVATIVES FOR THE PRESERVATION AND PROTECTION OF BIOLOGICAL MATERIALS AND MICROORGANISMS | TFCHEM (FR) | 2017-01-19 | — | — | US | disclosed |
| EP-3098893-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SOLUTION SECONDARY BATTERY USING SAME | Mitsubishi Chemical Corporation (JP) | 2016-11-30 | — | — | EP | disclosed |
| US-20160211553-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2016-07-21 | — | — | US | disclosed |
| US-9175044-B2 | Derivatives of glyco-CF2-serine and glyco-CF2-threonine | TFCHEM (FR) | 2015-11-03 | — | — | US | disclosed |
| US-20140255433-A1 | PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140105839-A1 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | TF-CHEM (FR) | 2014-04-17 | — | — | US | disclosed |
| US-8486897-B2 | C-aryl glycoside compounds for the treatment of diabetes and obesity | TFCHEM (FR) | 2013-07-16 | — | — | US | disclosed |
| US-20130171180-A1 | DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE | TFCHEM (FR) | 2013-07-04 | — | — | US | disclosed |
| US-20130123264-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISORDERS AND INTESTINAL CANCERS | Georgia Health Sciences University | 2013-05-16 | — | — | US | disclosed |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20110034402-A1 | C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY | TFCHEM | 2011-02-10 | — | — | US | disclosed |
| US-5744676-A | DIMERIZATION, CATALYSTS | AMOCO CORPORATION | 1998-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140105839-A1 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | SLC5A2, SLC5A1, SLC2A2 | CA2 1240/4885 |
| US-20130123264-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISORDERS AND INTESTINAL CANCERS | PRKG2, PDE5A, PRKG1 | CA2 1724/4885 |
| US-20130059844-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE2A | CA2 1494/4885 |
| US-20140255433-A1 | PDE5 INHIBITOR COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | PDE5A, PDE3A, PDE2A | CA2 437/4885 |
| US-20110034402-A1 | C-ARYL GLYCOSIDE COMPOUNDS FOR THE TREATMENT OF DIABETES AND OBESITY | SLC5A2, SLC5A1, GPR119 | CA2 858/4885 |
| US-20130171180-A1 | DERIVATIVES OF GLYCO-CF2-SERINE AND GLYCO-CF2-THREONINE | PTMS, SLC5A2, INF2 | CA2 908/4885 |
| US-20170015709-A1 | GLYCOPEPTIDE DERIVATIVES FOR THE PRESERVATION AND PROTECTION OF BIOLOGICAL MATERIALS AND MICROORGANISMS | GLA, GLB1, GALR1 | CA2 4241/4885 |
| US-20170224691-A1 | PDE INHIBITORS IN IMMUNOTHERAPY | PDE5A, PDE2A, PDE3A | CA2 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.